FDA approvals you might have missed
A look at 5 recent approvals from the US Food and Drug Administration (FDA), including treatment for systemic lupus erythematosus, a new gene therapy, and pain relief for patients with irritable bowel syndrome.
The US Food and Drug Administration (FDA) has approved dalteparin sodium (FRAGMIN, Pfizer, Inc.) for patients aged 1 month and older. The drug is the first FDA-approved treatment for venous thromboembolism(VTE) in pediatric patients. It is give subcutaneously twice daily, up to 3 months.
Recent Videos
RX Review: Emerging research shaping the future of food allergy care in 2025
RX Review: Closing knowledge gaps in pediatric allergy management
RX Review: The role of needle-free epinephrine in pediatric allergy for 2025
RX Review: Addressing unmet needs in food allergy diagnosis and care
RX Review: Advances in pediatric food allergy and anaphylaxis treatment
2025 immunization update: addressing vaccine hesitancy and catch-up vaccinations
How canceled government agency meetings could impact vaccination schedules, with Mary Koslap-Petraco, DNP
Glycemic control guidelines for critically ill children with Maureen Madden, DNP
Key Takeaways on the Evolving Landscape of Pediatric Atopic Dermatitis Treatment
Tina Tan, MD, on ACIP meeting postponement, public vaccine information reports
Related Content
